Cue Biopharma, Inc. (CUE) Operating Margin
- Operating margin · 12 months: Value -262.02%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -262.02% | Operating income / revenue. Period ending 2026-06-30. $-98.67M ÷ $37.66M × 100 ≈ -262.02% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -98.67M USD | Operating Income (Loss) |
| Revenue | 37.66M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 77.19M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-98.67M | $37.66M | (m) | $77.19M | (m) | -262.02% |
| 2026-03-31 | $-19.61M | $32.73M | (m) | $36.09M | (m) | -59.90% |
| 2025-12-31 | $-26.55M | $27.47M | (m) | $37.74M | (m) | -96.67% |
| 2025-09-30 | $-38.16M | $7.10M | (m) | $28.39M | (m) | -537.51% |
| 2025-06-30 | $-39.38M | $8.29M | (m) | $33.02M | (m) | -475.31% |
| 2025-03-31 | $-41.13M | $7.99M | (m) | $34.64M | (m) | -514.72% |
| 2024-12-31 | $-41.50M | $9.29M | (m) | $36.30M | (m) | -446.86% |
| 2024-09-30 | $-45.70M | $9.53M | (m) | $40.00M | (m) | -479.43% |
| 2024-06-30 | $-48.30M | $8.29M | (m) | $40.49M | (m) | -582.33% |
| 2024-03-31 | $-51.44M | $7.02M | (m) | $41.61M | (m) | -732.72% |
| 2023-12-31 | $-52.15M | $5.49M | (m) | $40.80M | (m) | -949.89% |
| 2023-09-30 | $-53.18M | $3.82M | (m) | $41.25M | (m) | -1392.14% |
| 2023-06-30 | $-52.79M | $1.79M | (m) | $38.94M | (m) | -2950.54% |
| 2023-03-31 | $-52.37M | $432.23K | (m) | $37.89M | (m) | -12115.58% |
| 2022-12-31 | $-53.22M | $1.25M | (m) | $38.58M | (m) | -4274.31% |
| 2022-09-30 | $-46.25M | $9.35M | (m) | $38.75M | (m) | -494.76% |
| 2022-06-30 | $-48.22M | $11.68M | (m) | $42.44M | (m) | -412.97% |
| 2022-03-31 | $-45.43M | $14.39M | (m) | $41.61M | (m) | -315.76% |
| 2021-12-31 | $-43.71M | $14.94M | (m) | $41.35M | (m) | -292.56% |
| 2021-09-30 | $-46.79M | $7.16M | (m) | $37.85M | (m) | -653.33% |
| 2021-06-30 | $-43.93M | $5.47M | (m) | $34.10M | (m) | -803.00% |
| 2021-03-31 | $-44.57M | $3.81M | (m) | $33.46M | (m) | -1170.52% |
| 2020-12-31 | $-45.04M | $3.15M | (m) | $33.55M | (m) | -1427.96% |
| 2020-09-30 | $-43.08M | $3.73M | (m) | $32.51M | (m) | -1155.56% |
| 2020-06-30 | $-40.05M | $4.01M | (m) | $30.29M | (m) | -999.10% |
| 2020-03-31 | $-38.34M | $3.99M | (m) | $29.04M | (m) | -961.24% |
| 2019-12-31 | $-36.77M | $3.46M | (m) | $27.49M | (m) | -1063.21% |
| 2019-09-30 | $-38.72M | $2.74M | (m) | $27.35M | (m) | -1413.37% |
| 2019-06-30 | $-44.38M | $2.20M | (m) | $32.36M | (m) | -2012.91% |
| 2019-03-31 | $-42.60M | $1.32M | (m) | $31.08M | (m) | -3223.48% |
| 2018-12-31 | $-38.70M | $1.14M | (m) | $28.54M | (m) | -3386.71% |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $-23.23M | (m) | (m) | $18.90M | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |